Clene (NASDAQ: CLNN) Making Strides in Neurodegenerative Disease Treatment
Clene (NASDAQ: CLNN) is advancing in the treatment of ALS, MS, and PD with its innovative nanotherapeutic platform and lead drug candidate, CNM-Au8.
This news matters because Clene's innovative nanotherapeutic platform and lead drug candidate, CNM-Au8, have the potential to transform the lives of millions suffering from ALS, MS, and PD. The company's mission to improve mitochondrial health and protect neuronal function could significantly impact the treatment of neurodegenerative diseases.
